PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd.'s NDA Submission of Alogliptin in Japan

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (NASDAQ:PPDI) today confirmed that Takeda Pharmaceutical Company Limited has submitted a new drug application for alogliptin, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, to the Ministry of Health, Labour and Welfare in Japan. PPD partnered with Takeda to develop the compound.

Back to news